Answers are grounded in this paper and cite their sources.
Small bowel cancer explains the following parameters such as malignancy, common sites, subtypes, symptoms, investigations, management and complications. · Small bowel malignancy: rare, ~1,900 cases/yr in UK; <5% of GI cancers despite comprising 90% of mucosal surface. · Common sites: duodenum (55-82%), jejunum (11-25%), ileum (7-17%). Risk factors, · Subtypes: adenocarcinoma (40%, duodenum, avg. age 66), neuroendocrine tumours (ileum), lymphoma (coeliac disease-related EATL), Kaposi sarcoma (HHV-8, immunocompromised). · Risk factors: Male, age, African ethnicity, celiac disease, Crohn's disease, FAP, and Lynch syndrome are non-modifiable; smoking, alcohol, obesity, poor fiber, and a diet heavy in red meat are modifiable. · Symptoms: non-specific abdominal pain, weight loss, occult/microscopic GI bleeding, anaemia; may cause gastric outlet or small bowel obstruction. · Investigations: FBC (anaemia), iron studies, LFTs (mets), stool FIT, genetic testing; imaging—CT, PET-CT, MRI enterography, capsule endoscopy, biopsy. · Management: Chemotherapy (5-FU, capecitabine, oxaliplatin), immunotherapy (pembrolizumab), radiation (palliative), surgical excision (segmental or Whipple's for duodenal tumors), and careful waiting (low-risk cases). · Complications: obstruction (gastric/small bowel), perforation, iron deficiency anaemia, nmetastasis (liver, lungs, bone, brain), death; prognosis—53% 5-year survival.
No takes yet. Share an insight, caveat, or question.
E. et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: